During the second week of November 2026 (covering Nov 6th–13th), major developments across European HealthTech and MedTech centred on UK public-sector digital infrastructure, regulatory shifts, early-stage capital trends, and major industry summits.

Oura has spent a decade telling people what their bodies are doing. On Tuesday it paid $625 million for the ability to do something about it. The smart-ring maker has agreed to buy Counsel Health, an AI-native virtual primary care company, in an all-cash deal expected to close before the end of 2026. Counsel pairs a chat-based medical AI with its own board-certified physicians, who can join a conversation within minutes to diagnose, prescribe and refer. The service already si

The primary bottleneck confronting digital health investors is no longer technical feasibility or software development velocity, but enterprise procurement friction, health system architectural integration, and the structural realisation of Distributed to Paid In capital (DPI).

Oracle Health, the business built on Cerner, is not officially for sale. Oracle has announced no process, and every public statement since January says it is doubling down. Yet the question refuses to die, because Oracle's balance sheet keeps asking it.

The earn-out used to be the clause everyone hoped to delete before signing. In European HealthTech, MedTech and Health AI it has quietly become the deal itself. A founder selling a Series B diagnostics company in Munich, a PE-backed buyer consolidating radiology AI across the Nordics, a US strategic picking up a UK remote-monitoring business: in each case, a meaningful slice of the price, often 20 to 50 per cent, now sits behind a set of post-completion conditions.

In November 2026, San Francisco-based voice artificial intelligence developer Ellipsis Health completed the acquisition of New York-based care navigation startup Kouper Health for an undisclosed valuation. The transaction represents an operational transition within digital health: the migration of conversational voice AI from standalone acoustic observation into closed-loop, deterministic execution across clinical workflows.

The European HealthTech and MedTech ecosystem has seen notable moves across clinical AI deployment, funding, and major ecosystem gatherings: Several major developments have emerged across the European Health AI ecosystem this week, spanning new early-stage funding, clinical AI validation, market consolidation analysis, and regulatory policy milestones:

Fertifa, the London healthtech run by venture capitalist Eileen Burbidge, has agreed to buy Tuune, a women's health company whose regulated clinical software helps clinicians deliver personalised hormonal care. The deal, first reported by Sky News, is expected to be announced this week. Its value is not being disclosed.

Every European health fund raised between 2019 and 2022 now holds companies that are alive, off plan and unlikely to raise another priced round. They are not the winners that will return the fund, and they are not the write-offs that have already been taken. They sit in the middle: a CE-marked device with slow hospital uptake, a digital therapeutic with a reimbursement code in one country and nothing elsewhere, a health AI company whose models are good but whose NHS or German

Nelson Advisors has spent 2026 doing two things at once: closing lower-mid-market healthtech deals and telling the rest of the market what it sees. The London-based firm, co-founded by partners Lloyd Price and Paul Hemings, specialises in mergers, acquisitions, partnerships and investments for HealthTech, MedTech, Digital Health, Health IT and Health AI companies with enterprise values between roughly $25 million and $250 million.

KPMG’s 2026 healthcare technology report, based on interviews with 128 senior healthcare technology executives at organisations with revenues above US$1 Billion, finds a sector investing heavily in digital transformation but still struggling to convert that spend into measurable value. KPMG describes organisations as sitting in one of three modes: stabilising core platforms and data integrity, synchronising systems and governance, or scaling AI across workflows at enterprise

Nelson Advisors: Heidi Health, Best Practice and the challenge facing clinical AI is not accuracy of ML models, but access to data infrastructure and integration permissions within established systems. The primary care health technology landscape is undergoing a structural transition from assistive ambient transcription utilities to autonomous, agentic artificial intelligence systems. For several years, ambient voice technology (AVT) operated as a non-invasive layer at the cl

The European lower mid market across healthcare technology, medical technology (MedTech) and clinical artificial intelligence (AI) encompassing enterprises generating between €5 million and €50 million in revenue, enterprise values of €25 million to €250 million, and operating EBITDA of €1 million to €10 million, is entering a distinct developmental cycle. Following the contraction of venture-backed expansion that characterised 2022 through 2024, the market has undergone a st

Major strategic investments in surgical robotics, regulatory adaptations under the EU MDR/IVDR, and cross-border hardware deals highlight the European MedTech sector this week: Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV.

The foundational work, titled "Medical superintelligence: foundations and aspirations" (authored by Xiaoxuan Liu, Mayank Daswani, Christopher Kelly, Harsha Nori, Nicola Ding, Matthew M. Nour, Emma Rocheteau, Craig Sherstan, Viknesh Sounderajah, Adrian D. Haimovich, Eric Topol, Mustafa Suleyman, Dominic King, and Eric Horvitz), defines medical superintelligence not as superhuman accuracy on isolated tasks, but as the capacity to surpass the strongest contemporary human-led hea